University of Utah
http://www.utah.edu
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From University of Utah
Atavistik Bio Raises $60m For Metabolic Disease, Cancer Drug Discovery
The preclinical start-up is identifying allosteric binders that can inhibit or activate metabolic proteins. Atavistik will focus on genetically defined diseases then test its candidates in broader populations.
With First IND, Recursion Readies Its AI, Experimental Biology Approach For The Clinic
Emerging Company Profile: With an early focus on rare, monogenic diseases, Recursion believes its platform combining artificial intelligence and experimental biology can be applied to any disease that can be modeled on a cellular level.
Genentech Bets On Kineta's Early-Stage, Disease-Modifying Pain Therapy
Genentech partners with the Seattle biotech on a non-opioid approach to chronic pain. Kineta says there's disease-modifying potential.
VC Roundup: Early-Stage Funding Slips Again In Third Quarter, Plus 15 New Financings
Early-stage venture capital funding continues to decline, but corporate VC dollars and other sources of cash are emerging to fund startups. Also, biopharma companies raised $436.3m in 15 recent financings.
Company Information
- Industry
- Academic and Research Institutions